- Home
- CARS vs CDNA Comparison
CARS vs CDNA Comparison
Compare CARS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- CDNA
- Stock Information
- Founded
- CARS 1998
- CDNA 1998
- Country
- CARS United States
- CDNA United States
- Employees
- CARS N/A
- CDNA N/A
- Industry
- CARS Motor Vehicles
- CDNA Medical Specialities
- Sector
- CARS Consumer Discretionary
- CDNA Health Care
- Exchange
- CARS Nasdaq
- CDNA Nasdaq
- Market Cap
- CARS 815.4M
- CDNA 712.2M
- IPO Year
- CARS 2017
- CDNA 2014
- Fundamental
- Price
- CARS $12.36
- CDNA $15.19
- Analyst Decision
- CARS Strong Buy
- CDNA Buy
- Analyst Count
- CARS 5
- CDNA 8
- Target Price
- CARS $17.30
- CDNA $26.86
- AVG Volume (30 Days)
- CARS 784.0K
- CDNA 1.3M
- Earning Date
- CARS 11-06-2025
- CDNA 11-03-2025
- Dividend Yield
- CARS N/A
- CDNA N/A
- EPS Growth
- CARS 69.36
- CDNA N/A
- EPS
- CARS 0.63
- CDNA 1.00
- Revenue
- CARS $717,845,000.00
- CDNA $340,826,000.00
- Revenue This Year
- CARS $2.52
- CDNA $12.73
- Revenue Next Year
- CARS $2.93
- CDNA $11.90
- P/E Ratio
- CARS $19.61
- CDNA $15.23
- Revenue Growth
- CARS 0.68
- CDNA 14.72
- 52 Week Low
- CARS $9.56
- CDNA $10.96
- 52 Week High
- CARS $20.47
- CDNA $32.76
- Technical
- Relative Strength Index (RSI)
- CARS 42.96
- CDNA 60.38
- Support Level
- CARS $11.99
- CDNA $14.28
- Resistance Level
- CARS $13.85
- CDNA $15.21
- Average True Range (ATR)
- CARS 0.41
- CDNA 0.60
- MACD
- CARS -0.10
- CDNA 0.02
- Stochastic Oscillator
- CARS 19.95
- CDNA 72.48
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.